Guardant Health, Inc. (NASDAQ:GH – Get Free Report) insider John Saia sold 20,000 shares of the stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the completion of the transaction, the insider directly owned 45,950 shares in the company, valued at $4,894,134.50. The trade was a 30.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Guardant Health Stock Up 0.8%
Shares of NASDAQ GH traded up $0.94 during mid-day trading on Friday, reaching $118.95. 2,633,856 shares of the company were exchanged, compared to its average volume of 2,090,416. Guardant Health, Inc. has a 52 week low of $36.36 and a 52 week high of $121.01. The company’s 50 day moving average price is $90.53 and its 200 day moving average price is $98.79. The stock has a market capitalization of $15.77 billion, a PE ratio of -35.09 and a beta of 1.48.
Guardant Health (NASDAQ:GH – Get Free Report) last released its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same quarter in the previous year, the company posted ($0.62) earnings per share. The firm’s revenue was up 39.4% compared to the same quarter last year. On average, sell-side analysts predict that Guardant Health, Inc. will post -2.92 earnings per share for the current year.
Institutional Investors Weigh In On Guardant Health
Analysts Set New Price Targets
Several brokerages have recently commented on GH. BTIG Research increased their price objective on Guardant Health from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Barclays upped their target price on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. UBS Group reissued a “buy” rating and set a $175.00 price target on shares of Guardant Health in a research note on Friday, January 30th. Citigroup boosted their price objective on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Finally, Canaccord Genuity Group increased their target price on shares of Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, February 20th. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $129.00.
Get Our Latest Stock Analysis on GH
Guardant Health Company Profile
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Stories
- Five stocks we like better than Guardant Health
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
